Welcome to our dedicated page for Avalon Globocare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon Globocare stock.
Avalon GloboCare Corp. (NASDAQ: ALBT) generates news across precision diagnostics, cellular therapy intellectual property, generative AI software, and commercial real estate. Company press releases describe Avalon as a commercial‑stage developer of precision diagnostic consumer products, with a flagship focus on the KetoAir™ handheld breathalyzer for ketogenic health management. News coverage frequently highlights deployments of KetoAir™ in wellness initiatives, first responder programs, and international online sales channels.
Investors following ALBT news will see updates on distribution agreements, affiliate marketing programs, and partnerships that incorporate KetoAir™ as a real‑time metabolic monitoring tool. Recent announcements include collaborations with Saga Health Corporation and SpecialtyHealth, Inc. for first responder wellness programs, as well as expansion of KetoAir™ availability into the United Kingdom through online sales. Avalon also reports on its co‑development agreement with Qi Diagnostics Limited to create a VOC nanosensor‑based cannabis breathalyzer aimed at supporting detection of potential cannabis‑impaired driving.
Beyond diagnostics, Avalon’s news flow includes developments in its cellular therapy intellectual property portfolio, such as the issuance of a Hong Kong patent for proprietary CAR‑T and CAR‑NK cell technology co‑developed with Arbele Limited. The company also issues updates on its acquisition of RPM Interactive, Inc. and the Catch‑Up generative AI SaaS platform, which is designed to automate short‑form video creation and support marketing for KetoAir™ and other consumer health products.
Regulatory and corporate actions also feature in ALBT news, including SEC filings, financing transactions, Nasdaq listing compliance updates, and progress on the proposed merger with YOOV Group Holding Limited. Readers can use this news stream to monitor how Avalon’s precision diagnostics, AI‑driven software, cellular therapy IP, and capital markets activities evolve over time.
Avalon GloboCare (NASDAQ: ALBT) has secured a new patent in Hong Kong for its proprietary CAR-T and CAR-Natural Killer (NK) cell technology. The patent (No. HK40074322), co-developed with Arbele Limited, provides 20-year protection effective from February 21, 2020.
The technology features a bispecific Anti-CD19xCD22 CAR design targeting both CD19 and CD22 antigens to reduce tumor escape risk, and a localized cytokine induction system aimed at enhancing immune responses at tumor sites. This patent complements Avalon's existing protections in the United States and other PCT jurisdictions, strengthening their position in cell-based immunotherapy development.
Avalon GloboCare (NASDAQ: ALBT) has entered into a definitive agreement with Qi Diagnostics to co-develop a VOC nanosensor-based cannabis breathalyzer. The collaboration will involve Avalon, its subsidiary Q&A Distribution, and Qi Diagnostics working together to design, validate, and develop a prototype device aimed at detecting potential cannabis-impaired driving in real-time.
The partnership combines Avalon's regulatory expertise with Qi Diagnostics' VOC nanosensor technology to create a non-invasive cannabis detection solution for law enforcement and workplace safety applications.
Avalon GloboCare (NASDAQ: ALBT) has filed a registration statement on Form S-4 with the SEC for its proposed merger with YOOV Group Holding. The merger will be executed through Avalon's subsidiary, Nexus MergerSub, with YOOV becoming a wholly-owned subsidiary of Avalon.
The combined entity will focus on providing Artificial Intelligence-as-a-Service (AIaaS) solutions, specializing in intelligent business automation. The merger aims to create a public company that will help organizations optimize operations, reduce costs, and enhance service delivery through AI technology.
The deal's completion depends on key conditions, including:
- Approval from Avalon stockholders
- Nasdaq Stock Market approval for YOOV listing post-merger
Avalon GloboCare (NASDAQ: ALBT) has partnered with SpecialtyHealth to enhance the BrAce 4 Impact Challenge (B4IC) using their KetoAir™ breathalyzer. The collaboration, launched on April 1, 2024, integrates SpecialtyHealth into Avalon's Zero to Keto Affiliate Marketing Program and B4IC Series.
The program combines Pounds Transformation's 4-week diet program with SpecialtyHealth's 'Famous Police Panel' wellness initiatives, targeting police chiefs across multiple states. The KetoAir™ device, FDA-registered (number: 3026284320), measures breath acetone concentration to track ketosis levels through nano-sensor technology.
This partnership focuses on supporting law enforcement officers in maintaining their health goals through real-time ketone monitoring. The device's pocket-sized design allows officers to check their ketone levels between shifts, providing immediate feedback and accountability in their wellness journey.
Avalon GloboCare (NASDAQ: ALBT) has secured a patent in China for its CAR-T and CAR-NK cell technology, valid for 20 years from April 4, 2025. The patent, titled 'Artificial Immunosurveillance Chimeric Antigen Receptor and Cells Expressing the Same,' was granted by the China National Intellectual Property Administration under No. CN 114502188 B.
Co-developed with Hong Kong-based Arbele , the technology features a bispecific Anti-CD19xCD22 CAR design targeting both CD19 and CD22 antigens to reduce tumor escape risk, and a localized cytokine induction mechanism to enhance CAR cell performance. The patent complements existing protections in the U.S. and other PCT territories, strengthening Avalon's global intellectual property portfolio in cell-based immunotherapy.
Avalon GloboCare (NASDAQ: ALBT) has partnered with Pounds Transformation Clinics to launch the 'BrAce 4 Impact Challenge Series,' featuring their KetoAir™ breathalyzer devices. The partnership includes placing KetoAir devices on consignment at three Connecticut locations.
Following a successful pilot program ending March 18, 2025, the first official challenge begins April 1, 2025. The KetoAir device, FDA-registered (No. 3026284320), measures breath acetone concentration to track ketosis status through nano-sensor technology, accessible via Apple App Store and Google Play Store.
Early results show promising outcomes, with pilot participants reporting significant weight loss success while maintaining BrAce readings around 12ppm. Pounds Transformation plans to initiate new challenges every six weeks, supported by dedicated coaches for daily participant guidance.
Avalon GloboCare (NASDAQ: ALBT) has announced a definitive merger agreement with YOOV, a leading business AI automation solutions provider. The merged entity will operate as YOOV and trade under the ticker 'YOOV' on Nasdaq, pending approval.
YOOV demonstrated strong financial performance with unaudited revenue of $45.7 million and net income of $3.4 million for calendar year 2024, compared to $28.7 million revenue and $2.4 million net loss in 2023, representing 59.1% annual revenue growth.
Post-merger ownership structure will see YOOV shareholders holding approximately 97.5-97.8% of the combined company, while Avalon shareholders will retain 2.2-2.5%. The transaction is expected to close in Q3 2025, subject to stockholder approval. Phil Wong will serve as Chairman, CEO, and President of the combined company, with a seven-member board comprising five YOOV and two Avalon designees.
Avalon GloboCare (NASDAQ: ALBT) has received a Notice of Allowance from China's National Intellectual Property Administration for patent AVAR1901CN, co-developed with Arbele The patent covers innovative CAR-T and CAR-NK cell technology, extending Avalon's intellectual property beyond the U.S. and PCT territories.
The technology features a bispecific Anti-CD19xCD22 CAR design targeting both CD19 and CD22 antigens to minimize tumor escape risk. It also includes a localized cytokine induction system that enhances CAR cell effectiveness and activates anti-tumor immune responses specifically upon tumor engagement.
According to CEO David Jin, this platform technology aims to provide practical, cost-effective solutions for point-of-care cancer treatment, potentially improving accessibility and patient outcomes globally.
Avalon GloboCare (NASDAQ: ALBT), a precision diagnostics and laboratory services developer, has received notice from Nasdaq on November 19, 2024, confirming its regained compliance with the exchange's minimum bid price requirement under Rule 5550(a)(2). The company's CEO, David Jin, emphasized their commitment to shareholders and corporate governance, stating their continued focus on creating sustainable long-term value for both shareholders and stakeholders.
Avalon GloboCare (NASDAQ: ALBT) has launched the 'BrAce for Impact' affiliate marketing program for KetoAir™, an AI-enabled breathalyzer device for ketogenic health monitoring. The program, developed following demand from recent health conferences, offers affiliates discount codes and commissions on sales.
The initiative provides marketing materials and brand resources to affiliates, targeting metabolic coaches, podcasters, health authors, and influencers. KetoAir™, FDA-registered (No. 3026284320), measures breath acetone concentration using nano-sensor technology to assess ketosis status, with companion apps available on both Apple and Google platforms.